CalciMedica Announces Presentations at Upcoming Medical Meetings
CalciMedica Announces Presentations at Upcoming Medical Meetings
Details for the presentations are as follows:Prof. Robert Sutton to deliver plenary presentation on Phase 2b CARPO trial of Auxora in Acute Pancreatitis (AP) at American Pancreatic Association (APA) 2024 Annual Meeting
罗伯特·萨顿教授将在2024年美国胰腺协会(APA)年会上就Auxora在急性胰腺炎(AP)中的20亿CARPO试验进行大会演讲。
Poster presentation on Phase 2b CARPO trial at Emergencies in Medicine (EIM) 2024 Meeting
在2024年医学紧急情况(EIM)会议上进行20亿CARPO试验的海报展示。
LA JOLLA, Calif., Nov. 20, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the acceptance of an abstract for plenary presentation at the American Pancreatic Association (APA) 2024 Annual Meeting being held December 9-10 in Maui, HI, and the acceptance of an abstract for poster presentation at the Emergencies in Medicine (EIM) 2024 Meeting being held December 8-13 in Maui, HI.
加利福尼亚州拉荷亚，2024年11月20日 /PRNewswire/ -- 中国飞机租赁公司(CalciMedica) (纳斯达克: CALC)，是一家专注于开发新型钙释放活化钙(CRAC)通道抑制疗法，治疗急性和慢性炎症及免疫疾病的临床阶段生物医药公司，今天宣布接受在美国胰腺协会(APA)2024年年会上的大会演讲摘要，会议将于12月9日至10日在夏威夷毛伊岛举行，同时也接受在2024年医学紧急情况(EIM)会议上的海报展示摘要，会议将在12月8日至13日在夏威夷毛伊岛举行。
Details for the presentations are as follows:
演讲详情如下:
Plenary Presentation at APA 2024 Annual Meeting
在APA 2024年年会的大会报告
Presentation Title: Auxora Decreases the Development of Severe Organ Failure in Patients with Acute Pancreatitis and SIRS
报告标题：Auxora减少急性胰腺炎和全身炎症反应综合症(SIRS)患者严重脏器衰竭的发展
Presenter: Prof. Robert Sutton, B.A. (Hons), M.B., B.S., D.Phil., FRCS, University of Liverpool and Liverpool University Hospitals NHS Foundation Trust
主讲人：罗伯特·萨顿亿曰.A.（荣誉）万.b.亿.S.、D.Phil.、FRCS，利物浦大学和利物浦大学医院NHS基金会托管
Session Title: Abstract Session 2 – Pancreatitis
会议标题：摘要会议2 - 胰腺炎
Session Date and Time: Tuesday, December 10, 8:00-9:30 a.m. HST
会议日期和时间：2023年12月10日（星期二），上午8:00-9:30 HST
Poster Presentation at EIM 2024 Meeting
EIm 2024会议的海报展示
Presentation Title: A Randomized, Double-Blind, Placebo Controlled Dose Ranging Study of Auxora in Patients with Acute Pancreatitis (AP) and Accompanying Systemic Inflammatory Response Syndrome (SIRS)- CARPO (NCT0468106)
报告标题：Auxora在急性胰腺炎（AP）患者及伴随的全身性炎症反应综合症（SIRS）中的随机双盲安慰剂对照剂量调整研究- CARPO (NCT0468106)
The presentation and poster will be available following the sessions on the Medical Events & Presentations section of CalciMedica's IR website at .
报告和海报将在会议后在CalciMedica的IR网站的医疗活动与报告部分提供。
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced topline data for a Phase 2b trial (called CARPO – NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS) and completed a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – NCT06374797) in patients with acute kidney disease (AKI) with associated acute hypoxemic respiratory failure (AHRF) with data expected in 2025 and continuing to support the ongoing Phase 1/2 trial (called CRSPA – NCT04195347) in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT) with data expected in 2025. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit .
CalciMedica是一家致力于开发新型CRAC通道抑制剂治疗炎症和免疫疾病的临床生物制药公司。CalciMedica的专有技术针对CRAC通道的抑制作用可调节免疫反应，从而保护组织细胞，有潜力在当前没有已批准疗法的危及生命的炎症和免疫性疾病中提供治疗效益。CalciMedica的主要产品候选药物Auxora已经在多项完成的疗效性临床试验中展现出积极和一致的临床结果，对于第二期临床试验具有参考意义。奇泊 -NCT04681066）和冠状病毒性肺炎患者的第2期临床试验（名为CARDEA -NCT04345614）已经完成，继续支持正在进行的第1/2AIPT研究（名为CRSPA -NCT04195347），预计在2025年公布数据，并已启动其第2项研究（名为KOURAGE -NCT06374797），预计在2025年公布基于与AHRF相关的AKI的数据。 CalciMedica由来自Torrey Pines Therapeutics和哈佛CBR生物医学研究所的科学家创立，总部位于加利福尼亚州拉荷亚。有关更多信息，请访问。
CalciMedica是一家临床阶段的生物制药公司，专注于开发用于治疗炎症和免疫疾病的新型CRAC通道抑制剂疗法。CalciMedica的专有技术针对CRAC通道的抑制，以调节免疫反应，保护组织细胞免受损伤，具有在目前尚无批准疗法的危及生命的炎症和免疫疾病中提供治疗益处的潜力。CalciMedica的主打产品Auxora在多个完成的有效性临床试验中显示出积极且一致的临床结果。CalciMedica已宣布急性胰腺炎（AP）和伴有全身性炎症反应综合症（SIRS）患者20亿临床试验的顶线数据（称为CARPO – NCT04681066），并已完成针对COVID肺炎患者的Phase 2临床试验（称为CARDEA – NCT04345614）。该公司目前正在对伴随急性缺氧呼吸衰竭（AHRF）的急性肾病（AKI）患者进行Phase 2临床试验（称为KOURAGE – NCT06374797），预计在2025年获得数据，并继续支持针对因天冬氨酸酶引起的胰腺毒性（AIPT）儿童患者的正在进行的Phase 1/2临床试验（称为CRSPA – NCT04195347），预计在2025年获得数据。CalciMedica由来自Torrey Pines治疗公司和哈佛CBR生物医学研究所的科学家创立，总部位于加利福尼亚州拉荷亚。欲了解更多信息，请访问。
Forward-Looking Statements
This communication contains forward-looking statements which include, but are not limited to, CalciMedica's ongoing and planned clinical trials and the timing, design, expected patient enrollment thereof and the expected timing for the release of data from those trials, including its Phase 2b CARPO trial of Auxora for AP with accompanying SIRS, its ongoing Phase 1/2 CRSPA trial of Auxora in pediatric patients with AIPT, and its planned Phase 2 KOURAGE trial of Auxora in AKI with associated AHRF; the potential benefits of Auxora for the treatment of AP, AKI and AIPT; and the potential of CalciMedica's proprietary technology to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. CalciMedica's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances. Risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption "Risk Factors" in CalciMedica's Annual Report on Form 10-K for the year ended December 31, 2023, and elsewhere in CalciMedica's subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at www.sec.gov. These documents can be accessed on CalciMedica's web page at ir.calcimedica.com/financials-filings/sec-filings. The forward-looking statements contained herein are made as of the date hereof, and CalciMedica undertakes no obligation to update them after this date, except as required by law.
前瞻性声明
本通讯包含前瞻性声明，其中包括但不限于CalciMedica正在进行和计划的临床试验及其时机、设计、预期患者招募情况以及这些试验数据发布的预期时间，包括其针对伴随SIRS的AP的Phase 20亿 CARPO试验、正在进行的针对儿童AIPt患者的Phase 1/2 CRSPA试验，以及计划中的针对AKI和相关AHRF的Phase 2 KOURAGE试验；Auxora在AP、AKI和AIPT治疗中的潜在好处；以及CalciMedica专有科技在危及生命的炎症和免疫疾病中提供治疗益处的潜力。这些前瞻性声明遵循1995年《私人证券诉讼改革法》的安全港条款。CalciMedica对这些事项的预期和信念可能不会实现。实际结果和结果可能与这些前瞻性声明中考虑的情况存在重大差异，这些差异可能是由不确定性、风险和情况变化引起的。可能导致实际结果与前瞻性声明中考虑的情况存在重大差异的风险和不确定性已包含在CalciMedica截至2023年12月31日的年度报告的“风险因素”标题下，以及在CalciMedica随后向SEC提交的10-k、10-Q或8-k表格的其他地方，这些文件可随时在www.sec.gov上获得。这些文件可以在CalciMedica的网页ir.calcimedica.com/financials-filings/sec-filings上访问。本声明中的前瞻性陈述是在此日期作出的，CalciMedica没有义务在此日期之后更新这些声明，法律要求的除外。
CalciMedica Contact:
CalciMedica联系方式：Sarah Sutton / Kevin Murphy
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
[email protected]
(212) 600-1902
投资者和媒体
阿哥特合伙人。
来源：CalciMedica, Inc.
[email protected]
（212）600-1902
SOURCE CalciMedica, Inc.
源自CalciMedica，Inc。
